Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - A literature review by Verhaart IEC et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This work is licensed under a Creative Commons Attribution 4.0 International License 
 
 
Newcastle University ePrints - eprint.ncl.ac.uk 
 
Verhaart IEC, Robertson A, Wilson IJ, Aartsma-Rus A, Cameron S, Jones CC, 
Cook SF, Lochmuller H. 
Prevalence, incidence and carrier frequency of 5q-linked spinal muscular 
atrophy - A literature review. 
Orphanet Journal of Rare Diseases 
2017, 12(1) 
 
 
Copyright: 
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons 
Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits 
unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to 
the original author(s) and the source, provide a link to the Creative Commons license, and indicate if 
changes were made. The Creative Commons Public Domain Dedication waiver 
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, 
unless otherwise stated. 
DOI link to article: 
https://doi.org/10.1186/s13023-017-0671-8  
Date deposited:   
24/07/2017 
REVIEW Open Access
Prevalence, incidence and carrier frequency
of 5q–linked spinal muscular atrophy –
a literature review
Ingrid E. C. Verhaart1, Agata Robertson1, Ian J. Wilson2, Annemieke Aartsma-Rus1, Shona Cameron1,
Cynthia C. Jones3, Suzanne F. Cook4 and Hanns Lochmüller1*
Abstract: Spinal muscular atrophy linked to chromosome 5q (SMA) is a recessive, progressive, neuromuscular disorder
caused by bi-allelic mutations in the SMN1 gene, resulting in motor neuron degeneration and variable presentation in
relation to onset and severity. A prevalence of approximately 1–2 per 100,000 persons and incidence around 1 in
10,000 live births have been estimated with SMA type I accounting for around 60% of all cases. Since SMA is a relatively
rare condition, studies of its prevalence and incidence are challenging. Most published studies are outdated and
therefore rely on clinical rather than genetic diagnosis. Furthermore they are performed in small cohorts in small
geographical regions and only study European populations. In addition, the heterogeneity of the condition can lead to
delays and difficulties in diagnosing the condition, especially outside of specialist clinics, and contributes to the
challenges in understanding the epidemiology of the disease. The frequency of unaffected, heterozygous
carriers of the SMN1 mutations appears to be higher among Caucasian and Asian populations compared to
the Black (Sub-Saharan African ancestry) population. However, carrier frequencies cannot directly be translated
into incidence and prevalence, as very severe (death in utero) and very mild (symptom free in adults)
phenotypes carrying bi-allelic SMN1 mutations exist, and their frequency is unknown.
More robust epidemiological data on SMA covering larger populations based on accurate genetic diagnosis or
newborn screening would be helpful to support planning of clinical studies, provision of care and therapies
and evaluation of outcomes.
Keywords: Spinal muscular atrophy, Prevalence, Incidence, Carrier frequency, Ethnic background
Background
Spinal muscular atrophy (SMA) is characterised by de-
generation of the alpha motor neurons of the spinal cord
anterior horn cells, leading to progressive proximal
muscle weakness and atrophy and, in the most severe
types, paralysis.
The clinical phenotype of SMA is heterogeneous, ran-
ging from a severe to a mild phenotype. It is generally
divided into three main subtypes: type I (also called
Werdnig Hoffmann disease), type II and, type III (also
called Kugelberg Welander disease). However, these
phenotypes are seen more as a continuum rather than as
distinct subtypes and sometimes further subtypes at both
ends of the spectrum are observed. SMA type 0 is a very
severe form with onset in utero, reduced or absent
movements, contractures, and requirement for mechan-
ical ventilation support at birth and death before six
months of age, while SMA type IV is a mild late (adult)
onset form that has a normal life expectancy [1, 2]. An
overview of the different subtypes is given in Table 1.
SMA is inherited in an autosomal recessive manner.
In most cases it is caused by mutations in the survival
motor neuron 1 (SMN1, SMNT, telomeric) gene, located
on chromosome 5q13.2 [3]. In rare cases (~4%) SMA is
caused by mutation in another gene (non-5q SMA). The
majority of the patients (92%) have a homozygous
deletion of SMN1. In the remaining patients small muta-
tions that abolish the production of the SMN protein
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are found, mostly in a combination with an SMN1
deletion (~4%) [4, 5]. A centromeric homologue of the
gene, SMN2, (previously also called SMNC or CBCD541)
is present in humans. SMN2 differs from SMN1 by five
nucleotides of which only one (an 840C➔T transition at
exon 6–7) lies in the coding sequence and is transitionally
silent. This change and a change in intron 7 cause exon 7
of the SMN2 transcript to be poorly recognized by the
splicing machinery, resulting in the skipping of this exon
in the majority of transcripts. This results in a frame-shift
and production of a protein with a different C-terminal
end, which is unstable and non-functional [3, 6]. Since
exon 7 is sometimes included in SMN2 transcripts, some
full-length SMN protein can be produced, albeit as very
low levels (~10–20%) that are insufficient to prevent
disease. The number of SMN2 copies varies within the
general population, and is inversely associated with disease
severity as having more SMN2 copies ensures that the
absolute amount of SMN protein that is produced is
higher. Notably, SMN2 defects in isolation do not seem to
cause the disease [7–9]. Other modifiers that might play a
role are NAIP, H4F5, GTF2H2 and PLS3 [10–15]. NAIP,
H4F5 and GTF2H2 are thought to be a modifiers due to
their proximity to the SMN1 gene and NAIP also shows
homology to apoptosis inhibitory proteins [12, 14, 16].
PLS3 restores the function of the neuromuscular junction,
by stabilizing F-actin-dependent endocytosis [17].
The first therapy for SMA, Spinraza (IONIS-SMNRx,
nusinersen), has recently been approved by the Food
and Drug Administration (FDA) in the US [18] and by
the European Medicines Agency (EMA) in Europe [19].
Clinical trials for other potential therapies are progres-
sing. As such, the knowledge about the frequency of the
disease becomes even more important. This review
provides an overview of what is currently known about
the prevalence, incidence and carrier frequency of SMA.
Methods
Published literature on prevalence, incidence or carrier
frequency of SMA was identified through PubMed
searches. Search terms were ‘spinal muscular atrophy’
OR ‘Werdnig Hoffmann’ OR ‘Kugelberg Welander’ AND
‘prevalence’ OR ‘incidence’, OR ‘carrier frequency’. No
restrictions for language were used; however articles in
other languages than English may be missed, due to the
use of English search terms. Retrieved literature was
scanned and all available articles performing a preva-
lence, incidence or carrier frequency study were used for
this review. Additional publications were identified from
references in the articles. Available literature published
through 6th December 2016 was taken into account; no
start date was used. For prevalence and incidence
studies, all studies had determining the prevalence and/
or incidence as primary goal. For carrier frequency
studies also studies in which carrier frequency was deter-
mined for other purposes were included. All articles
were appraised critically for accurate use of terminology
and were reassigned if needed. For detailed methods on
the analysis of carrier frequency differences between
ethnic groups see Additional file 1.
Prevalence and incidence of SMA
To date, only a few studies have been performed to
assess the prevalence and incidence of SMA. Most of
these have been conducted before 1995, when the
disease causing gene was identified, therefore using
clinical rather than genetic diagnosis as an inclusion
criterion. Generally, an estimation of the incidence of all
types of SMA of around 10 in 100,000 (1 in 10,000) live
births is cited [20, 21].
Prevalence
Prevalence is the number of living individuals with a
disease at a given time. An overview of the studies
examining the prevalence of SMA is provided in Table 2.
When examining all types of SMA together, in most
cases a prevalence of around 1–2 per 100,000 persons is
observed. In some studies a somewhat higher prevalence
was observed. A study from Bologna, Italy, in 1992
calculated a prevalence of 6.56 per 100,000 persons aged
less than 20 years [22]. Three studies in Scandinavia
showed a prevalence of 4.18 per 100,000 persons aged
18 years or less, and 3.23 and 2.78 per 100,000 persons
aged below 16 years [23–25]. This could indicate regional
differences in the incidence of SMA, i.e. gene pools.
However, there are several other factors that may account
for this observation. First of all, all studies were performed
in small regions and thereby small populations were
Table 1 Clinical classification of spinal muscular atrophy
SMA type OMIM number Age of onset Highest achieved motor function Natural age of death
0 - Prenatal/ Foetal Nil <6 months
I 253300 <6 months Sit with support only <2 years
II 253550 6–18 months Sit independently >2 years
III 253400 >18 months Stand and walk Adulthood
IV 271150 Adult (2nd or 3rd decade) Walk during adulthood Adult
OMIM Online Mendelian Inheritance in Man
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studied. For rare diseases like SMA, a small error in the
detection of the number of cases can have a large impact
on the estimated prevalence (sample bias). Secondly, these
studies only took children into account, which is likely to
influence the numbers in an upward direction. Further-
more, in the case of Sweden higher prevalence rates have
also been observed in studies into other neuromuscular
disorders, which could be due to a greater awareness and
a good health system in Sweden, making it easier to iden-
tify patients for such a study [26–28]. A study in North-
east Saudi Arabia also found a very high prevalence rate.
Although the prevalence of SMA might be different in the
Middle East when compared to Europe, in more than half
of the cases parental consanguinity was observed, which
could at least partially explain the high prevalence [29].
Prevalence by SMA subtype
Although SMA type I is expected to account for more
than half of all new SMA cases [30], the studies that ex-
amined a SMA type I only showed a prevalence of 0.04
to 0.28 per 100,000 [24, 25, 31–34], which is much lower
than the 1–2 per 100,000 persons noted for all SMA.
Due to its severity, patients with SMA type I have a
short life expectancy. Therefore often no or only few pa-
tients are alive on the date of the study, which could ac-
count for this lower prevalence. Nowadays, a median life
expectancy of around one year of age is estimated for
type I patients [35–37], whereas in type II 75–93% of
patients survive beyond 20 years of age [37–40] and life
expectancy for type III is thought to be close to the nor-
mal population [20, 39].
The prevalence of both SMA type II and III to-
gether has been estimated around 1.5 per 100,000
[31, 32, 41–43]. Of three studies that investigated
type II and type III separately, two found a higher
prevalence of type III compared to type II [24, 32].
This may be explained by the longer life expectancy
of type III patients compared to type II SMA
patients.
Incidence
Incidence is the number of new cases of disease in a par-
ticular time period. In the case of SMA, the genotype is
present at birth; a more precise term therefore is birth
prevalence. Since newborn screening is not widely per-
formed the number of patients expressing the phenotype
is used instead to estimate the incidence. An overview of
the studies examining the incidence is given in Table 3.
When evaluating the incidence of all types of SMA
combined, on average an incidence of around 8 per
100,000 live births is found (~1 in 12,000). Some studies
show a somewhat lower or higher incidence. In a study
in Iceland an incidence of 13.7 per 100,000 live births
was found. This is a study on an island with a relatively
small population, where it might be easier to identify all
patients. A study in Slovakia found a high incidence of
17.8 per 100,000, but details of the number of patients
or population size were unavailable, making it difficult
to interpret these findings [44]. In a recent study in
Cuba a lower incidence of 5.0 per 100,000 was seen [45].
Patients were detected via an obligatory governmental
registry and approximately 70% of the patients were
genetically confirmed. This study also examined the
ethnicity of the SMA type I patients. The majority of
these patients were White (30/36), 5/36 were of mixed
race and 1/36 patient was Black. Although this could be
partially explained by the racial composition of the
Cuban population, still relatively more White people
were affected. There are several reasons that could ac-
count for this. First, there is a difference in incidence be-
tween various ethnicities. There are also reports of lower
SMA carrier frequencies among Hispanics [46, 47].
However, it could also be the case that there are differ-
ences in the access to health care between different
ethnicities. In a small study among 75,000 persons in
Libya, a high incidence (24 per 100,000 live births) was
found, and this may partially be explained by a high de-
gree of consanguinity [48].
Incidence by subtype
In 1991, Alan Emery published a review estimating
the incidence for SMA type I to be around 4–6 in
100,000 (1 in 12,500–1 in 16,667) live births [49],
which was based on only three studies [50–52]. We
identified 17 studies, which taken together indicated
an SMA I incidence of approximately 6 per 100,000.
In the USA (North Dakota) in a study that pre-dated
genetic testing, high incidence was observed (14.9 per
100,000); however this study was performed in a very
small population, and any error in the accuracy of
case identification may be associated with the high
incidence. All patients studied were Caucasian and no
consanguinity was observed [53]. In a regional study in
Germany, a higher incidence of 9.8 per 100,000 was found
[33]. In Libya, a high incidence, as found for total SMA,
was not observed among type I patients (8.0 per 100,000)
[48]. This is again based on a small population and could
be due to a lack of awareness of SMA at the time the
study was conducted. Furthermore, SMA type I patients
might have been missed due to their short life span. In
two small communities a very high incidence was
observed. On Reunion Island in a European community a
founder effect (loss of genetic variation that occurs when
a new population is established by a very small number of
individuals, which could lead to a high incidence if in one
of these founders a mutation was present) was clearly
seen, leading to an incidence of 79 per 100,000. In an
Egyptian Karaite community in Israel, where in more than
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half of the affected families consanguinity was observed,
an incidence of as high as 250 per 100,000 live births was
found.
For type II and III, a high incidence of both types
combined was observed (10.6 per 100,000) in a German
study in the same region as the previously mentioned
type I study that partially covered the same time period
[33, 43]. The healthcare system in Germany may partly
explain these observations. Furthermore, there might be
regional differences in SMA incidence. The authors sug-
gest that SMA might be more prevalent in central and
Eastern Europe than in Western Europe. For type II and
type III SMA the highest occurrence was observed in
Libya (16 per 100,000) [48].
A study not added in Table 3 is a study from Kurland
et al. in Rochester, USA, studying the period 1945–1954.
This study found only one SMA type I patient and the
calculations used the total population size instead of the
number of live births to calculate the incidence. Further-
more, this total population consisted of only 30,000
persons [54].
The epidemiologic burden of SMA is not equally di-
vided over the subtypes. In 2004 Ogino et al. reviewed
several studies and calculated incidence rates of 5.83 per
100,000 live births for SMA type I, 2.66 per 100,000 live
births for type II and 1.20 per 100,000 live births for type
III. This implied that SMA type I, II and III constituted
60%, 27% and 12% of all SMA cases, respectively [30].
This overview included the study of Radhakrishan et al.
in Libya, in which for half of the families parental con-
sanguinity was observed [48]. In our analysis, we calcu-
lated the percentages in two ways yielding nearly
identical results. First by only taking studies into account
in which all types of SMA were studied separately, as
this makes a direct comparison possible; and, secondly
by taking all studies presented into account. In both
cases this resulted in incidence rates of around 5.5, 1.9
and 1.7 per 100,000 for type I, II and III, respectively.
This yields a percentage of around 60% for the incidence
of SMA type I; with the remaining 40% of the cases
equally divided between type II and type III. This indi-
cates that SMA I indeed makes up the largest proportion
of the total SMA.
Considerations for comparing studies
To date, there are few studies of the prevalence and/or
incidence of SMA, with a small number of these being
recent. Most of the studies have been carried out in
Europe. Furthermore, four of the ten studies done out-
side of Europe were performed in the countries with
high consanguinity or small communities, thereby they
are not considered to be representative of the overall
SMA prevalence and incidence. No worldwide studies
have been published to date.
A number of limitations should be taken into
account when estimating prevalence/ incidence of
SMA and comparing the presented studies. Most
studies have been performed before 1995 when the
genetic cause for SMA, deletion of the SMN1 gene,
was identified [3], where after genetic diagnosis was
implemented. Therefore, most studies rely on the less
accurate clinical diagnosis of SMA. This increases the
chance of misdiagnosis of diseases with clinical fea-
tures similar to SMA. Another difficulty comparing
studies is that the classification of SMA has slightly
changed over the years and it is not always clear
which classification system has been used. For
example, in the studies of John Pearn in Northeast
England patients were defined as SMA type I if they
had an onset of symptoms before the age of
12 months, so this might also include some early di-
agnosed SMA type II patients [41, 52]. Chronic SMA
was classified as patients living beyond 18 months
old. However, in the study in West-Thüringen,
Germany patients had to survive till at least four
years of age to be classified as chronic SMA [43].
This is further exemplified by the study of Spiegler
et al. in Warsaw, Poland. In this study type Ib
patients are mentioned, and are defined as patients
diagnosed at birth or in the first months of life and
living up to 30 years, whereas type II SMA was
described as having an onset at the age of one year
onwards [42]. In the study of Zellweger et al. in
Switzerland it is not clearly specified which defini-
tions were used, but it is conceivable that some type
II patients are included in the numbers of type I
patients [55]. Currently, the classification of the
main subtypes: I, II and III (and sometimes IV) as
described in Table 1 is used.
Another factor that should be taken into account is
that the studies have been performed in different time
periods. The natural history of SMA has changed
over the years as the standards of care and associated
outcomes have largely improved in the recent years.
For example for type I comparison of studies showed
the mean age of death increased from 8.8–10 months
in studies performed before 1995 to 10.4 months up
to 4 years in studies performed after 2000 [35, 36].
This is partly due to the availability of assisted venti-
lation (non-invasive or through tracheostomy) and of
tube feeding through a gastrostomy [36].
Lastly, most of the studies have been performed in
small geographical areas, thereby including a relatively
small study population. One or two patients more or
less in a small patient population will have a strong
effect on the calculated prevalence or incidence. All
these factors make a comparison between the studies
and the interpretation of the findings difficult.
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In conclusion, few prevalence and incidence studies
have been performed for SMA, of which most are based
on clinical diagnosis and are performed in European
countries or regions, using small study populations. In
addition to prevalence and incidence studies, carrier
frequencies can provided useful additional information
about, for example, ethnic subpopulations.
Carrier frequency in SMA
Since SMA is a recessive disease, there are also un-
affected, heterozygous carriers of the disease. Carriers
fall into four main groups of genotypes (Fig. 1). The
most common one is the ‘1 + 0’ genotype (one normal,
functional allele and a SMN1 deleted, disease allele). A
much less common category is the ‘2 + 0’ genotype with
two functional genes on one chromosome and none on
the other. Furthermore, there are also ‘1 + 1D’ and
‘2 + 1D’ genotypes, which have one or two functional
genes on one chromosome and a non-functional gene
due to either a point mutation or a microdeletion on the
other. These last two genotypes are very rare [56, 57].
Four or even more copies of the SMN1 gene have also
been found, indicating a ‘2 + 2’ or possibly a ‘3 + 1’ geno-
type. This suggests ‘3 + 0’ or ‘3 + 1D’ carrier genotypes
might also be possible, however these will be even rarer.
No signs of disease have been associated with being
a carrier for SMA. However, some studies suggest
abnormal SMN1 copy numbers (either deletions or
duplications) may increase the risk and severity of
sporadic amyotrophic lateral sclerosis (ALS), although
other studies have been unable to confirm this associ-
ation (for a review see Butchbach et al., 2016 [58]).
Furthermore, it was suggested that in the rare dis-
order progressive muscular atrophy (PMA) SMN1 du-
plications might be associated with a more severe
clinical phenotype [59].
After the discovery of mutations in SMN1 as the
cause of SMA, several studies into the carrier status
of SMA have been performed. In contrast to the
prevalence/ incidence studies, most studies have been
performed outside of Europe. Some of these are
population screening programmes, whereas others are
large samples of the general population [46, 60–81].
There are also studies where small population sam-
ples were analysed or the carrier frequency was esti-
mated from healthy controls screened for SMN1 for
other purposes [8, 30, 82–99]. As mentioned before,
frequencies estimated from a small population sample
are less accurate. An overview of all studies is given
in Additional file 2.
Subpopulation differences
Some of the studies have examined differences between eth-
nic groups within their study population [46, 62–65, 77, 80].
The main finding was that copy numbers were significantly
higher in Black (Sub-Saharan African ancestry) people. This
was seen in African Americans [46, 62, 77], as well as in
Black Africans [66] and would indicate a higher
proportion of 2-copy (duplication) alleles, thereby
suggesting a higher number of ‘2 + 0’ carriers. This
could account for a lower detection rate (around 70%
for Black people versus 90–95% for other ethnicities),
leading to a high number of false negatives. The
study in Africa found a significantly lower carrier
frequency compared to Eurasians [66]. Lower carrier
frequencies were also seen in a study comparing
Black and White people in South Africa and a study
among samples of the 1000 genome project [65, 80].
However, these studies could not detect the ‘2 + 0’
carriers, which could reduce the observed differences.
Some studies also found lower carrier frequencies in
Non-carrier genotypes
SMN1
‘1+1’
‘2+1’
SMN1
SMN1 SMN1
SMN1
Carrier genotypes
SMN1
‘1+0’
‘2+0’
SMN1 SMN1
SMN1
‘1+1D’
SMN1
*
‘2+1D’
SMN1
*
SMN1 SMN1
*Point mutation or microdeletion.
Fig. 1 Most common SMA genotypes among non-carriers
and carriers
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Hispanics [46, 77], but this was not seen in other
studies [62, 69, 80]. Lastly, Luo et al. identified a spe-
cific haplotype, present in Ashkenazi Jews and Asians
detectable by microsatellite analysis, that could distinguish
duplication alleles (present in ‘2 + 0’ carriers) from normal
‘1 + 1’ genotypes [77].
We carried out an analysis of differences between eth-
nic groups and studies. Fig. 2 shows a comparison of all
studies described in Additional file 2 (ethnicities are in-
dicated). The grey area indicates the 95% confidence
interval based on the average carrier frequency of all
studies combined (0.019).1 Most studies fall within this
area, indicating no large differences in carrier frequency.
Two populations (a Muslim Arab village in Israel and a
specific group of Hutterites in South Dakota, USA)
showed a particularly high carrier frequency. However,
these are isolated populations with a high degree of in-
breeding [81, 89]. Also in an Iranian population a higher
carrier frequency was seen (1 in 20). However this is
based on one study with a small sample size, further-
more, in Iran, consanguineous marriages are common
[91]. Combined estimates of carrier frequencies for
ethnic groups were calculated (large symbols in Fig. 2
and Table 4).
The results show that the highest frequencies are
found in Caucasian and Asian populations (around 1 in
50) and the lowest in Black (1 in 100) and Hispanics (1
in 76) populations. However, it is important to note that
genetically Hispanics are a very mixed group, making
generalizations difficult. This is also demonstrated by
the fact that some studies among Hispanics found much
higher frequencies [69, 80], while others found that the
frequencies were lower [46].
SMN1 copy number differences between populations
In 2014, MacDonald et al. have performed a meta-
analysis comparing the SMA carrier frequency among
different ethnicities. In their analysis they included 14
studies where ethnicities were described and results were
broken down by SMA copy number [47]. They took the
different carrier genotypes described above into account
and determined the carrier rates in the ethnic groups.
Furthermore, they calculated the reduced risk of being a
carrier if a 2- or 3-copy result was found. This again
showed a substantially higher carrier risk with a 2-copy
test result for Black people. In addition a very high
carrier risk and 2-copy risk in Iranians was found. How-
ever, this is based on one study only [91].
The Additional file 3 shows all studies that examined
at the SMN1 copy number status. None of the studies
among Arabian populations performed this analysis,
therefore this group has not been included in the table.
SMN1 allele frequencies were determined for each group
(Table 5) using copy numbers (for methods and
calculations see Additional file 1).
The copy number 0 (carriers) is lower in Blacks and
Hispanics. Whilst there is not a great difference in the
two copy number frequencies between other ethnicities,
this is much higher in the Black population. As is seen
in Table 6, this indicates a higher number of hidden
carriers (‘2 + 0’ genotype), thereby decreasing the sensi-
tivity of most carrier tests used, which only measure the
copy numbers. Therefore, it is important to take the
ethnicity into account when performing population
screening or genetic counselling and consider a different
method to reduce the chance of false negative results. In
Table 6 also disease frequencies are estimated by
combining the copy number results with an estimated
small mutation (1D) frequency of 4% [4, 5] and an
estimated de novo mutation frequency of 2% [100].
Thereafter, the incidences rates were estimated using
these frequencies (Table 7).
The incorporation of estimated carrier risks for
people with a 2 copy number result, generates only a
slightly lower incidence (~1 in 54) for the Black pop-
ulations compared to most other populations (~1 in
45), due to presence of a much higher number of
multiple SMN1 copy number alleles in this
population. The estimation of the combined carrier
frequency in Hispanics is lower than in other
populations (1 in 65), as was also seen in the
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E
st
im
at
ed
 C
ar
rie
r 
F
re
qu
en
cy
0.
00
0.
02
0.
04
0.
06
0.
08
0.
10
0.
12
0.
14
10 100 1000 10000 100000
Muslim Israeli Arab village
Hutterites (Schmiedeleut)
Arab
Iran
Asian
Asian Indian
Black
Caucasian
Hispanic
Jewish
Fig. 2 Carrier frequency studies for SMA. The grey area represents
the 95% confidence interval based on the average carrier frequency
(0.019) of all individuals (except those from the isolated Muslim
Israeli Arab village and the Schmiedeleut Hutterites). Small dots
represent individual studies. In case studies seperated between
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previous estimations. It must be noted however that
here only a subset of studies is used compared to the
comparison of all studies (Fig. 2 and Table 4), which
can also contribute to differences in estimations.
The combined results lead to the highest incidence
estimations of around 1 in 8000 in Asians and
Caucasians, whilst lower incidence of around 1 in
20,000 are estimated in the Black and Hispanic
populations.
In Caucasians, the incidence rate estimated from car-
rier frequencies is higher than the observed incidence
rates in studies (Table 3, ~1 in 11,000). Carrier frequency
estimates are solely based on genetic studies, whilst most
incidence studies were based on clinical diagnosis and
are mostly much older. However, carrier frequency inci-
dence estimates could be an overestimation of the true
incidence due to reduced penetrance. Here a penetrance
of 100% is assumed. If the penetrance is decreased by
10% (i.e. penetrance of 90%) the incidence would also
decrease by 10%. It might be that some cases of SMA
are so severe that they lead to premature death in utero.
SMN2 is absent in 10–15% of the general population
[101], and deletions of both SMN1 and SMN2 are em-
bryonically lethal. Furthermore increased awareness
could lead to more genetic counselling of couples at risk,
certainly in couples who have previous children or fam-
ily members with SMA. In addition, sporadic cases of
unaffected individuals without functional SMN1 cases
have been described [96, 102–109]. This might be due to
high copy numbers of SMN2, since, as mentioned be-
fore, SMN2 copy number influences the severity of the
disease [7–9]. Therefore, it is important to take SMN2
copy number into account when performing newborn
screening.
Conclusions
SMA is a severe, heterogeneous, neuromuscular dis-
order. The few available prevalence and incidence
studies mainly predate genetic testing and were per-
formed in small geographical areas, mainly in Europe.
This highlights the need for larger, more generalizable
prevalence studies.
Recently, carrier frequency of SMA in healthy
populations has been studied quite extensively,
indicating differences between ethnicities not only in
carrier frequency, but also in copy number status. In
some groups this decreases the sensitivity of
commonly used carrier testing methods. This
Table 4 Carrier frequencies for SMA per ethnicity
Population Number of identified carriers Number of study participants Carrier frequency 95% CI
Araba 152 9058 0.017 0.014–0.019
Asian 2492 119,718 0.021 0.020–0.022
Asian Indian 20 1465 0.014 0.008–0.020
Black (Sub-Saharan ancestry) 80 8012 0.010 0.008–0.012
Caucasian 680 31,549 0.022 0.020–0.023
Hispanic 127 9649 0.013 0.011–0.015
Jewish 1059 59,196 0.018 0.017–0.019
Median and 95% posterior intervals of SMA carrier frequencies, based on studies presented in Additional file 2. Only ethnicities studied in more than one study
are included
CI confidence interval
a) The isolated Muslim Israeli Arab village [59] has been omitted
Table 5 SMN1 allele frequencies per ethnicity
Frequency by number of SMN1 copies on a single allele
0 Copies 1 Copy 2 Copies
Ethnicitya Portion 95% CI Portion 95% CI Portion 95% CI
Asian 0.010 0.010–0.011 0.949 0.948–0.950 0.040 0.039–0.041
Asian Indianb 0.010 0.006–0.015 0.908 0.894–0.921 0.082 0.070–0.095
Black (Sub-Saharan ancestry) 0.007 0.005–0.009 0.717 0.708–0.725 0.276 0.268–0.285
Caucasian 0.011 0.010–0.012 0.954 0.952–0.955 0.035 0.034–0.037
Hispanic 0.007 0.006–0.008 0.915 0.911–0.919 0.078 0.074–0.082
Jewish 0.010 0.009–0.011 0.934 0.931–0.936 0.057 0.054–0.059
Median and 95% posterior intervals of copy number allele frequency, based on studies presented in Additional file 3
CI confidence interval
a) Same ethnicities as in Table 4 are included
b) Only consists of one study
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emphasizes the need to use methods that enable to
detect carriers having two SMN1 copies on one
chromosome and none on the other.
Good epidemiological data is needed to gain insight
into health care needs and for research studies and
clinical trials. This is especially important in rare dis-
eases where clinical trials require a careful planning.
Furthermore, newborn screening will become increas-
ingly important, especially now a drug has been
approved and other new therapies are in advanced clin-
ical trial stages. The introduction of new therapies is also
likely to impact on the prevalence of SMA and as such
may have significant resource implications for health
care planning.
Endnotes
1Two studies in studies in populations with a high
inbreed rate (a Muslim Arab village in Israel and a
Hutterite community in South Dakota, USA) are not in-
cluded in the average.
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